Johnson & Johnson (NYSE:JNJ) Shares Sold by Addenda Capital Inc.

Addenda Capital Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 43,857 shares of the company’s stock after selling 1,451 shares during the period. Addenda Capital Inc.’s holdings in Johnson & Johnson were worth $6,529,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Lake Point Wealth Management increased its position in Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after purchasing an additional 169 shares during the last quarter. Islay Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $42,000. FAI Wealth Management increased its position in Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC increased its position in Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. Finally, Crewe Advisors LLC increased its position in Johnson & Johnson by 909.1% during the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock worth $50,000 after purchasing an additional 300 shares during the last quarter. 67.44% of the stock is owned by hedge funds and other institutional investors.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by corporate insiders.

Shares of JNJ stock opened at $148.10 on Friday. The company has a market capitalization of $389.92 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The firm has a fifty day simple moving average of $148.57 and a 200-day simple moving average of $146.59. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.12 earnings per share. Equities research analysts predict that Johnson & Johnson will post 8 EPS for the current year.

Several equities research analysts have issued reports on JNJ shares. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Raymond James boosted their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of “Buy” and a consensus price target of $164.93.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply